验证2021年EASL新算法在NAFLD晚期纤维化无创诊断中的价值
FIB4/VCTE联合专利血清学算法的诊断准确率约85%,仅需10%患者行肝活检;基层/糖尿病门诊队列肝活检需求仅3%,阳性预测值75%。研究验证了该算法在NAFLD晚期纤维化诊断中的效能。
要点
- 两种无创检测联用较单用可提高特异性及阳性预测值约20%,支持EASL序贯策略。
- FIB4/VCTE/FibroMeter与FIB4/VCTE/Fibrotest算法诊断准确率约85%,肝活检需求率仅10%。
- 基层/糖尿病门诊队列应用EASL算法,肝活检需求率仅3%,三步一致阳性预测值75%。
核心结论
- 本研究验证了EASL 2021年指南提出的算法可用于NAFLD晚期纤维化的无创诊断。
研究设计与样本
- 396例患者有ELF评分;另纳入230例来自基层/糖尿病门诊、有FIB4、VCTE和ELF的患者队列。
主要发现
- 两种无创检测联用较单用可提高特异性及阳性预测值约20%。
- FIB4/VCTE/FibroMeter与FIB4/VCTE/Fibrotest算法表现相似,诊断准确率约85%,肝活检需求率仅10%。
- 在ELF可用的亚组中,FIB4/VCTE/ELF算法表现相似。
- 模拟显示患病率从15%起阳性预测值升至75%以上平台,阴性预测值在患病率25%以下保持90%以上,肝活检需求率在低与高患病率间仅增加5%。
- 基层/糖尿病门诊队列应用EASL算法,肝活检需求率仅3%,三步一致阳性预测值75%。
关键数值与推荐
- FIB4/VCTE/FibroMeter与FIB4/VCTE/Fibrotest算法诊断准确率约85%,肝活检需求率仅10%。
- EASL算法在基层/糖尿病门诊队列中肝活检需求率仅3%,阳性预测值75%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The European Association for the Study of the Liver (EASL) has recently proposed an algorithm for the diagnosis of advanced liver fibrosis. We aimed to evaluate the diagnostic accuracy of this algorithm in nonalcoholic fatty liver disease (NAFLD). APPROACH AND RESULTS: One thousand fifty-one patients with NAFLD, liver biopsy, and four noninvasive tests (NITs; Fibrosis-4 [FIB4], vibration controlled transient elastography [VCTE], FibroMeter, Fibrotest) were included. The enhanced liver fibrosis (ELF) score was available in 396 patients. A cohort of 230 patients from primary care/diabetes clinics had FIB4, VCTE, and ELF. Compared with the performance of single NITs, agreement between two NITs (FIB4 and VCTE, VCTE and patented serum tests) increased specificity and positive predictive value by 20%, thus justifying the sequential use proposed in the EASL algorithm. The FIB4/VCTE/FibroMeter and FIB4/VCTE/Fibrotest algorithms performed similarly, providing 85% diagnostic accuracy and a liver biopsy requirement rate of only 10%. The FIB4/VCTE/ELF algorithm performed similarly in the subgroup where ELF was available. Simulations of algorithm accuracies at different prevalence showed that positive predictive values rapidly increased, reaching a plateau above 75% starting at 15% prevalence. Negative predictive values remained higher than 90% up to 25% prevalence. The rate of liver biopsy requirement remained stable, increasing by only 5% between low and high prevalence settings. When the EASL algorithm was applied in the primary care/diabetes clinic cohort, liver biopsy requirement was only 3%, and the agreement among the three steps provided 75% positive predictive value. CONCLUSIONS: Our study validates the algorithm proposed by the EASL in its latest 2021 guidelines for the diagnosis of advanced fibrosis in the setting of NAFLD.
引用
- Canivet CM, Costentin C, Irvine KM, et al. Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD. Hepatology. 2023. PMID: 35822302. doi:10.1002/hep.32665
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。